News
Germany’s Merck KGaA to acquire CT-based bioscience company in $3.9B deal
Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday announced a definitive agreement to be acquired by Germany-based Merck KGaA in a deal valued at about $3.
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.
FRANKFURT (REUTERS) -German healthcare and materials group Merck KGaA said on Monday it struck ... to boost its cancer drug business. Darmstadt, Germany-based Merck said in a statement that ...
Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback